Study identifies potential way to slow or block progression of age-related macular degeneration
7 Articles
7 Articles
What might cancer treatment teach us about retinal disease? — Harvard Gazette
Health What might cancer treatment teach us about dealing with retinal disease? Joan Miller’s innovative thinking led to therapies for macular degeneration that have helped millions, made her better leader Sy Boles Harvard Staff Writer June 24, 2025 6 min read Part of the Profiles of Progress series Joan Miller says retinal surgeons tend to be a pretty open-minded bunch. “We’r…
A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration
Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the developed world. While treatment is effective for the neovascular or “wet” form of AMD, no therapy is successful for the non-neovascular or “dry” form. Here we discuss the current knowledge on dry AMD pathobiology and propose future research directions that would expedite the development of new treatments. In our view, these should emphasize sys…
Novel study uncovers the critical role of ADAM10 protein in the development of retinal disorders
New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) regulates abnormal blood vessel growth in the damaged retina, which can cause vision loss or impairment.
Study identifies potential way to slow or block progression of age-related macular degeneration
A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression of age-related macular degeneration, a leading cause of blindness in people over age 50.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium